{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:25:21Z","timestamp":1715991921551},"reference-count":36,"publisher":"Nihon University School of Dentistry","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Oral Science","J Oral Sci"],"published-print":{"date-parts":[[2017]]},"DOI":"10.2334\/josnusd.16-0241","type":"journal-article","created":{"date-parts":[[2017,3,30]],"date-time":"2017-03-30T22:33:41Z","timestamp":1490913221000},"page":"147-155","source":"Crossref","is-referenced-by-count":6,"title":["Effect of bisphosphonate as an adjunct treatment for chronic periodontitis on gingival crevicuar fluid levels of nuclear factor-\u03baB ligand (RANKL) and osteoprotegerin in postmenopausal osteoporosis"],"prefix":"10.2334","volume":"59","author":[{"given":"Feyza O.","family":"\u00d6zden","sequence":"first","affiliation":[{"name":"Department of Periodontology, School of Dentistry, Ondokuz Mayis University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elif E.","family":"Sakallio\u011flu","sequence":"additional","affiliation":[{"name":"Department of Periodontology, School of Dentistry, Ondokuz Mayis University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esra","family":"Demir","sequence":"additional","affiliation":[{"name":"Department of Periodontology, School of Dentistry, Ondokuz Mayis University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bir\u015fen","family":"Bilgici","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, School of Medicine, Ondokuz Mayis University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d6zg\u00fcr K.","family":"Tun\u00e7el","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, School of Medicine, Ondokuz Mayis University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feyzi","family":"G\u00f6kosmano\u011flu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, School of Medicine, Ondokuz Mayis University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ay\u015feg\u00fcl","family":"Atmaca","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, School of Medicine, Ondokuz Mayis University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1160","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Rogers A, Eastell R (2005) Circulating osteoprotegerin and receptor activator for nuclear factor \u03baB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 90, 6323-6331.","DOI":"10.1210\/jc.2005-0794"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C et al. (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315-323.","DOI":"10.1038\/16852"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Gori F, Hofbauer L, Dunstan C, Spelsberg T, Khosla S, Riggs B (2000) The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology 141, 4768-4776.","DOI":"10.1210\/en.141.12.4768"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, L\u00fcthy R et al. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309-319.","DOI":"10.1016\/S0092-8674(00)80209-3"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423, 337-342.","DOI":"10.1038\/nature01658"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Nagasawa T, Kiji M, Yashiro R, Hormdee D, Lu H, Kunze M et al. (2007) Roles of receptor activator of nuclear factor-\u03baB ligand (RANKL) and osteoprotegerin in periodontal health and disease. Periodontol 2000 43, 65-84.","DOI":"10.1111\/j.1600-0757.2006.00185.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Lerner UH (2006) Inflammation-induced bone remodeling in periodontal disease and the influence of post-menopausal osteoporosis. J Dent Res 85, 596-607.","DOI":"10.1177\/154405910608500704"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Lerner UH (2006) Bone remodeling in post-menopausal osteoporosis. J Dent Res 85, 584-595.","DOI":"10.1177\/154405910608500703"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Mogi M, Otogoto J, Ota N, Togari A (2004) Differential expression of RANKL and osteoprotegerin in gingival crevicular fluid of patients with periodontitis. J Dent Res 83, 166-169.","DOI":"10.1177\/154405910408300216"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Cochran DL (2008) Inflammation and bone loss in periodontal disease. J Periodontol 79, 8 Suppl, 1569-1576.","DOI":"10.1902\/jop.2008.080233"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Lane JM, Russell L, Khan SN (2000) Osteoporosis. Clin Orthop Relat Res 372, 139-150.","DOI":"10.1097\/00003086-200003000-00016"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Wactawski-Wende J (2001) Periodontal diseases and osteoporosis: association and mechanisms. Ann Periodontol 6, 197-208.","DOI":"10.1902\/annals.2001.6.1.197"},{"key":"13","unstructured":"13. Juluri R, Prashanth E, Gopalakrishnan D, Kathariya R, Devanoorkar A, Viswanathan V et al. (2015) Association of postmenopausal osteoporosis and periodontal disease: a double-blind case-control study. J Int Oral Health 7, 119-123."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Mart\u00ednez-Maestre M\u00c1, Gonz\u00e1lez-Cejudo C, Machuca G, Torrej\u00f3n R, Castelo-Branco C (2010) Periodontitis and osteoporosis: a systematic review. Climacteric 13, 523-529.","DOI":"10.3109\/13697137.2010.500749"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Genco RJ, Borgnakke WS (2013) Risk factors for periodontal disease. Periodontol 2000 62, 59-94.","DOI":"10.1111\/j.1600-0757.2012.00457.x"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD et al. (1991) Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88, 2095-2105.","DOI":"10.1172\/JCI115539"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Licata AA (2005) Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother 39, 668-677.","DOI":"10.1345\/aph.1E357"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Palomo L, Bissada NF, Liu J (2005) Periodontal assessment of postmenopausal women receiving risedronate. Menopause 12, 685-690.","DOI":"10.1097\/01.gme.0000184421.50696.34"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Pan B, Farrugia AN, To LB, Findlay DM, Green J, Lynch K et al. (2004) The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-\u03b1 converting enzyme (TACE). J Bone Miner Res 19, 147-154.","DOI":"10.1359\/jbmr.2004.19.1.147"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Dobnig H, Hofbauer LC, Viereck V, Obermayer-Pietsch B, Fahrleitner-Pammer A (2006) Changes in the RANK ligand\/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporos Int 17, 693-703.","DOI":"10.1007\/s00198-005-0035-4"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Reddy MS, Morgan SL (2013) Decreased bone mineral density and periodontal management. Periodontol 2000 61, 195-218.","DOI":"10.1111\/j.1600-0757.2011.00400.x"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Lane N, Armitage GC, Loomer P, Hsieh S, Majumdar S, Wang HY et al. (2005) Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study. J Periodontol 76, 1113-1122.","DOI":"10.1902\/jop.2005.76.7.1113"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9, 1137-1141.","DOI":"10.1002\/jbmr.5650090802"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Silness J, Loe H (1964) Periodontal disease in pregnancy. II. Correlation between oral hygiene and periodontal condition. Acta Odontol Scand 22, 121-135.","DOI":"10.3109\/00016356408993968"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Loe H, Silness J (1963) Periodontal disease in pregnancy. I. Prevalence and severity. Acta Odontol Scand 21, 533-551.","DOI":"10.3109\/00016356309011240"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Armitage GC (1999) Development of a classification system for periodontal diseases and conditions. Ann Periodontol 4, 1-6.","DOI":"10.1902\/annals.1999.4.1.1"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA et al. (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356, 1809-1822.","DOI":"10.1056\/NEJMoa067312"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Uematsu S, Mogi M, Deguchi T (1996) Interleukin (IL)-1\u03b2, IL-6, tumor necrosis factor-\u03b1, epidermal growth factor, and \u03b22-microglobulin levels are elevated in gingival crevicular fluid during human orthodontic tooth movement. J Dent Res 75, 562-567.","DOI":"10.1177\/00220345960750010801"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Bostanci N, Ilgenli T, Emingil G, Afacan B, Han B, T\u00f6z H et al. (2007) Gingival crevicular fluid levels of RANKL and OPG in periodontal diseases: implications of their relative ratio. J Clin Periodontol 34, 370-376.","DOI":"10.1111\/j.1600-051X.2007.01061.x"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Bab\u00fcr C, \u00d6zcan G, \u00c7ebi DU, Pervane B, \u00d6zdemir B, Y\u00fccel A et al. (2012) Gingival crevicular fluid levels of osteoprotegerin (OPG) in premenopausal and postmenopausal women with or without chronic periodontitis. J Dent 40, 364-371.","DOI":"10.1016\/j.jdent.2012.01.013"},{"key":"31","doi-asserted-by":"crossref","unstructured":"33. Bostanci N, Saygan B, Emingil G, Atilla G, Belibasakis GN (2011) Effect of periodontal treatment on receptor activator of NF-\u03baB ligand and osteoprotegerin levels and relative ratio in gingival crevicular fluid. J Clin Periodontol 38, 428-433.","DOI":"10.1111\/j.1600-051X.2011.01701.x"},{"key":"32","doi-asserted-by":"crossref","unstructured":"34. Balli U, Aydogdu A, Dede FO, Turer CC, Guven B (2015) Gingival crevicular fluid levels of sclerostin, osteoprotegerin, and receptor activator of nuclear factor-\u03baB ligand in periodontitis. J Periodontol 86, 1396-1404.","DOI":"10.1902\/jop.2015.150270"},{"key":"33","doi-asserted-by":"crossref","unstructured":"35. Bhavsar NV, Trivedi SR, Dulani K, Brahmbhatt N, Shah S, Chaudhri D (2016) Clinical and radiographic evaluation of effect of risedronate 5 mg as an adjunct to treatment of chronic periodontitis in postmenopausal women (12-month study). Osteoporos Int 27, 2611-2619.","DOI":"10.1007\/s00198-016-3577-8"},{"key":"34","doi-asserted-by":"crossref","unstructured":"36. Dundar U, Kavuncu V, Ciftci IH, Evcik D, Solak O, Cakir T (2009) The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study. J Bone Miner Metab 27, 464-470.","DOI":"10.1007\/s00774-009-0055-9"},{"key":"35","doi-asserted-by":"crossref","unstructured":"37. Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Koukoulis G, Kita M et al. (2008) Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial. Horm Metab Res 40, 281-285.","DOI":"10.1055\/s-2008-1046787"},{"key":"36","unstructured":"38. Verde ME, Bermejo D, Gruppi A, Gren\u00f3n M (2015) Effect of bisphosphonates on the levels of RANKL and OPG in gingival crevicular fluid of patients with periodontal disease and post-menopausal osteoporosis. Acta Odontol Latinoam 28, 215-221."}],"container-title":["Journal of Oral Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/josnusd\/59\/1\/59_16-0241\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T13:52:36Z","timestamp":1498398756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/josnusd\/59\/1\/59_16-0241\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2334\/josnusd.16-0241","relation":{},"ISSN":["1343-4934","1880-4926"],"issn-type":[{"value":"1343-4934","type":"print"},{"value":"1880-4926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}